

CITATION REPORT

List of articles citing

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial

DOI: 10.1016/j.amjhyper.2003.09.014
American Journal of Hypertension, 2004, 17, 103-11.

Source: <https://exaly.com/paper-pdf/37530848/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
454	Vasopeptidase inhibition improves insulin sensitivity and endothelial function in the JCR:LA-cp rat. 2004 , 44, 258-65		23
453	Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. 2004 , 102, 223-41		117
452	Optimizing hypertension and vascular health: focus on ethnicity. 2004 , 6, 28-38		8
451	Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. 2004 , 114, S51-131		490
450	The Author's Reply. 2004 , 64, 631		
449	Antagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomil. 2004 , 26 Suppl A, A12-20		12
448	Current World Literature. 2004 , 4, 329-334		
447	Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management. 2004 , 4, 267-70		60
446	Ethnicity and adverse drug reactions. 2005 , &NA;, 899-902		2
445	The kallikrein-kinin system: current and future pharmacological targets. 2005 , 99, 6-38		328
444	Cardiac natriuretic peptides for cardiac health. 2005 , 108, 23-36		74
443	Rationale for the use of angiotensin II receptor blockers in patients with left ventricular dysfunction (part I of II). 2005 , 28, 215-8		
442	The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. 2005 , S57-65		306
441	Antianginal efficacy of omapatrilat in patients with chronic angina pectoris. 2005 , 95, 1283-9		15
440	Angiotensin converting enzyme inhibitor-associated angioedema: More common than recognized. 2005 , 16, 37-42		
439	Expression of metallopeptidases and kinin receptors in swine oropharyngeal tissues: effects of angiotensin I-converting enzyme inhibition and inflammation. 2005 , 315, 1065-74		19
438	Losartan increases bradykinin levels in hypertensive humans. <i>Circulation</i> , 2005 , 111, 315-20	16.7	141

437	Evidence-based renal protection in cardiac surgery. 2005 , 9, 65-76	22
436	Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. 2005 , 315, 1306-13	22
435	The potential advantage of omapatrilat: dual anti-fibrotic and anti-inflammatory effects in one single molecule. 2005 , 23, 273-5	1
434	A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. 2005 , 77, 617-26	86
433	Mechanisms, pathophysiology, and therapy of arterial stiffness. 2005 , 25, 932-43	1183
432	[Multifactorial aspect of acute side effects of angiotensin converting enzyme inhibitors]. 2006 , 64, 276-86	3
431	Attenuation of cardiovascular remodeling in DOCA-salt rats by the vasopeptidase inhibitor, omapatrilat. 2006 , 28, 475-88	11
430	Angiotensin-converting enzyme inhibitor-associated angioedema. 2006 , 26, 725-37	109
429	Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). 2006 , 8, 649-56; quiz 657-8	35
428	[Antihypertensive drugs in clinical development]. 2006 , 127, 381-6	
427	Incidence and Characteristics of Angioedema Associated With Enalapril. 2006 , 2006, 80-81	
426	CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme. 2005 , 23, 317-30	30
425	Targeting proteases: successes, failures and future prospects. 2006 , 5, 785-99	988
424	A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of dual ACE/NEP inhibitor GW660511X in mild-to-moderate hypertensive patients. 2006 , 20, 496-503	8
423	Dual ACE/NEP inhibitors - more than playing the ACE card. 2006 , 20, 478-81	24
422	Brief review: angiotensin converting enzyme inhibitors and angioedema: anesthetic implications. 2006 , 53, 994-1003	40
421	Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. 2006 , 111, 909-27	91
420	The first preclinical pharmacotoxicological safety assessment of CGS 35601, a triple vasopeptidase inhibitor, in chronically instrumented, conscious, and unrestrained spontaneously hypertensive rats. 2006 , 29, 183-202	9

419	Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it. 2006 , 5, 643-9	47
418	Generalizing results of randomized trials to clinical practice: reliability and cautions. 2006 , 3, 508-12	53
417	CNP, but not ANP or BNP, relax human isolated subcutaneous resistance arteries by an action involving cyclic GMP and BKCa channels. 2006 , 7, 87-91	22
416	Vasopeptidase inhibition prevents target organ damage and improves survival in spontaneously hypertensive rats. 2006 , 7, 155-61	4
415	Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. 2006 , 48, 914-20	135
414	Hypertension. 2007 ,	
413	Novel drugs targeting hypertension: renin inhibitors and beyond. 2007 , 50, 3-8	6
412	Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. 2007 , 2007, 48-50	
411	Resistant or Difficult-to-Control Hypertension. 2007 , 2007, 10-12	
410	An update on non-peptide angiotensin receptor antagonists and related RAAS modulators. 2007 , 81, 615-39	48
409	Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. 2007 , 98, 57-63	97
408	Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema. 2007 , 120, 403-8	38
407	Natriuretic Peptides. 2007 , 349-362	1
406	Antihypertensive Drug Development: A Regulatory Perspective. 2007 , 535-548	
405	New and Investigational Drugs for Hypertension. 2007 , 295-302	0
404	Novel Drug Treatments for Hypertension. 2007 , 1049-1060	1
403	Angiotensin-Converting Enzyme Inhibitors. 2007 , 239-253	
402	Nonallergic angioedema: role of bradykinin. 2007 , 62, 842-56	170

401	Angiotensin-converting enzyme inhibitor-related angioedema: recognition and treatment. 2007 , 22, 47-51		6
400	Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. 2008 , 153, 947-55		103
399	Les effets secondaires aigus des inhibiteurs de l'enzyme de conversion de l'angiotensine dont l'angioedeme, differents dans leur biologie clinique, partagent une physiopathologie semblable. 2008 , 48, 434-440		0
398	Classification et diagnostic biologique des angioedemes. 2008 , 48, 441-446		2
397	Increasing hospitalizations due to angioedema in the United States. 2008 , 101, 185-92		47
396	Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. 2008 , 100, 327-32		156
395	Acute kidney injury and chronic kidney disease after cardiac surgery. 2008 , 15, 257-77		44
394	Investigational drugs for diabetic nephropathy. 2008 , 17, 1487-500		9
393	An update on hybrid drugs in cardiovascular drug research. 2008 , 3, 1397-408		3
392	Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. <i>American Journal of Hypertension</i> , 2008 , 21, 733-41	2.3	153
391	Is dipeptidylpeptidase IV the missing link in angiotensin-converting enzyme inhibitor--induced angioedema?. 2008 , 51, 45-7		5
390	Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. 2009 , 54, 516-23		148
389	"It's on the tip of my tongue". Isolated, ace-inhibitor related tongue swelling. 2009 , 64, 553-4		0
388	Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema. 2009 , 54, 468-70		21
387	Pharmaceutical Product Liabilities: A Review of Current Status and Future Trends. 2009 , 43, 253-261		
386	[Adverse drug reactions and the skin--from trivial to fire signal]. 2009 , 50, 171-8		3
385	Clinical Immunology Review Series: An approach to the patient with angio-oedema. 2009 , 155, 367-77		43
384	The impact of clinical trials legislation on clinical pharmacology: problems and solutions. 2009 , 67, 487-93		13

383	Next generation multifunctional angiotensin receptor blockers. 2009 , 32, 826-34	63
382	European Perspectives. <i>Circulation</i> , 2009 , 119,	16.7
381	Angioedema beyond histamine: an educational case series. 2009 , 64, 520-8	1
380	Long-term Effects of Renin-Angiotensin System Blocking Therapy and a Low Blood Pressure Goal on Progression of Hypertensive Chronic Kidney Disease in African Americans. 2009 , 2009, 47-48	1
379	Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. 2010 , 20, 532-6	59
378	New therapeutic approaches to resistant hypertension. 2010 , 12, 296-302	11
377	Central role of guanylyl cyclase in natriuretic peptide signaling in hypertension and metabolic syndrome. 2010 , 334, 53-65	11
376	A novel system for the investigation of microvascular dysfunction including vascular permeability and flow-mediated dilatation in pressurised human arteries. 2010 , 62, 40-6	6
375	Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension. 2010 , 12, 765-75	42
374	Effectiveness, safety and cost of drug substitution in hypertension. 2010 , 70, 320-34	36
373	Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use. 2010 , 65, 1381-7	29
372	Update on newer antihypertensive medicines and interventions. 2010 , 15, 257-67	4
371	Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-nepilysin inhibitor (ARNi). 2010 , 50, 401-14	337
370	Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and nepilysin: a randomised, double-blind, placebo-controlled, active comparator study. 2010 , 375, 1255-66	372
369	Combined neutral endopeptidase inhibitors. 2011 , 20, 457-63	19
368	Recent advances in the treatment of hypertension. 2011 , 9, 729-44	13
367	[Bradykinin mediated angioedema]. 2011 , 32, 225-31	12
366	Resistant hypertension workup and approach to treatment. 2010 , 2011, 598694	11

- 365 Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. **2011**, 57, 495-504 50
- 364 Pathophysiology of hereditary angioedema. **2011**, 25, 373-8 22
- 363 An atypical case of ARB-associated angioedema of the small intestine. **2011**, 24, E5-E8
- 362 Sodium and blood pressure in Africa. **2011**, 66, 541-4
- 361 Neprilysin, obesity and the metabolic syndrome. **2011**, 35, 1031-40 102
- 360 Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients. **2011**, 13, 506-16 18
- 359 The kidney as a target organ in pharmaceutical research. **2011**, 16, 244-59 2
- 358 Dual-acting angiotensin receptor-neprilysin inhibition. **2011**, 13, 74-8 10
- 357 Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. **2011**, 32, 2739-47 83
- 356 [Delayed angioedema during therapy with angiotensin-converting enzyme inhibitors]. **2011**, 68, 372-6 1
- 355 Renin-angiotensin system inhibitors and angioedema: anesthetic implications. **2012**, 25, 356-62 13
- 354 Many faces of angioedema: focus on the diagnosis and management of abdominal manifestations of hereditary angioedema. **2012**, 24, 353-61 31
- 353 Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. **2012**, 2012, 45-47
- 352 New drugs, procedures, and devices for hypertension. **2012**, 380, 591-600 115
- 351 Actualité biologiques sur les angioédèmes ðkinines. **2012**, 2012, 39-52
- 350 The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. **2012**, 380, 1387-95 756
- 349 Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure. **2012**, 385, 1117-25 11
- 348 Angiotensin receptor--neprilysin inhibitor (ARNI)--a novel therapeutic concept for management of hypertension and heart failure. **2012**, 21, 329-30 3

347	Penile angioedema developing after 3 years of ACEI therapy. 2012 , 43, 273-5	10
346	L'œdème laryngé induit par les médicaments interférant avec le métabolisme de la bradykinine. 2012 , 52, 157-159	1
345	Review article: the pathophysiological roles of the renin-angiotensin system in the gastrointestinal tract. 2012 , 35, 414-28	87
344	Relevant Practical Applications of Bioreduction Processes in the Synthesis of Active Pharmaceutical Ingredients. 2013 , 329-374	4
343	Pollen count and presentation of angiotensin-converting enzyme inhibitor-associated angioedema. 2013 , 1, 468-73.e1-4	7
342	Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). 2013 , 15, 1062-73	264
341	New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension. 2013 , 14, 285-9	11
340	[Management of angiotensin-converting enzyme inhibitor-related angioedema: recommendations from the French National Center for Angioedema]. 2013 , 34, 209-13	24
339	Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction. 2013 , 140, 156-66	11
338	The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure. 2013 , 22, 1041-7	11
337	Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition. 2013 , 22, 915-25	21
336	The past, present and future of renin-angiotensin aldosterone system inhibition. 2013 , 167, 1677-87	82
335	Endothelial permeability in vitro and in vivo: protective actions of ANP and omapatrilat in experimental atherosclerosis. 2013 , 48, 21-6	16
334	Targeting the renin-angiotensin-aldosterone system in heart failure. 2013 , 10, 125-34	72
333	Attenuation of increased secretory leukocyte protease inhibitor, matricellular proteins and angiotensin II and left ventricular remodeling by candesartan and omapatrilat during healing after reperfused myocardial infarction. 2013 , 376, 175-88	10
332	From bad behaviour to bad biology: pitfalls and promises in the management of resistant hypertension. 2013 , 29, 549-56	2
331	Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. 2013 , 34, 886-893c	175
330	Inhibición dual de la neprilisina y el receptor de angiotensina II: nueva estrategia prometedora en el tratamiento de la enfermedad cardiovascular. 2013 , 20, 386-393	4

329	RAAS inhibitors and cardiovascular protection in large scale trials. 2013 , 27, 171-9	66
328	Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. 2013 , 6, 594-605	98
327	Angiotensin-Converting Enzyme Inhibitors. 2013 , 179-190	
326	Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. 2013 , 23, 470-8	47
325	Life-threatening ACE inhibitor-induced angioedema after eleven years on lisinopril. 2013 , 26, 382-8	12
324	Factors associated with hospitalization of patients with angiotensin-converting enzyme inhibitor-induced angioedema. 2013 , 34, 267-73	13
323	Atrial natriuretic peptide and regulation of vascular function in hypertension and heart failure: implications for novel therapeutic strategies. 2013 , 31, 1061-72	19
322	Natriuretic peptides and cardio-renal disease. 2014 , 176, 630-9	78
321	Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat. 2014 , 32, 13-8	28
320	Targeting cardiac hypertrophy: toward a causal heart failure therapy. 2014 , 64, 293-305	55
319	PARADIGM-HF: Have we achieved a new paradigm in the treatment of heart failure?. 2014 , 2014, 224-7	3
318	Diagnosis and treatment of bradykinin-mediated angioedema: outcomes from an angioedema expert consensus meeting. 2014 , 165, 119-27	73
317	Current role of neprilysin inhibitors in hypertension and heart failure. 2014 , 144, 41-9	49
316	Novel blockers of the renin-angiotensin-aldosterone system in chronic heart failure. 2014 , 11, 31-9	3
315	Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. 2014 , 69, 602-16	410
314	Natriuretic peptides in cardiovascular diseases: current use and perspectives. 2014 , 35, 419-25	169
313	Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). 2014 , 16, 817-25	119
312	Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. 2014 , 63, 698-705	138

311	Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. 2014 , 2, 663-70	108
310	Angioedema deaths in the United States, 1979-2010. 2014 , 113, 630-4	38
309	Angiotensin-neprilysin inhibition versus enalapril in heart failure. 2014 , 371, 993-1004	3301
308	Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure. 2014 , 10, 543-57	14
307	Newest additions to heart failure treatment. 2014 , 15, 1849-61	1
306	Retrospective study of drug-induced anaphylaxis treated in the emergency department or hospital: patient characteristics, management, and 1-year follow-up. 2014 , 2, 46-51	59
305	Modulation of the renin-angiotensin-aldosterone system in heart failure. 2014 , 16, 403	13
304	Natriuretic Peptides and Cardiometabolic Health. 2015 , 79, 1647-55	51
303	Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review. 2015 , 35, 823-37	15
302	Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond. 2015 , 11, 283-95	15
301	An Unusual Case of Angiotensin-Converting-Enzyme Inhibitor-Related Penile Angioedema with Evolution to the Oropharynx. 2015 , 16, 1185-7	2
300	LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone. <i>American Journal of Hypertension</i> , 2015 , 28, 1409-17 ³	48
299	Novel Molecules. 2015 , 47-55	
298	Omapatrilat: penetration across the blood-brain barrier and effects on ischaemic stroke in rats. 2015 , 388, 939-51	1
297	Drug therapy for the patient with resistant hypertension. 2015 , 11, 191-202	1
296	The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention. 2015 , 201 Suppl 1, S15-22	20
295	New Drugs Under Development for Cardiovascular Prevention. 2015 , 323-334	1
294	Benzotriazole-Based Strategies Toward Peptidomimetics, Conjugates, and Other Peptide Derivatives. 2015 , 95-141	1

293	In vitro comparison of bradykinin degradation by aliskiren, a renin inhibitor, and an inhibitor of angiotensin-converting enzyme. 2015 , 16, 321-7		8
292	Natriuretic Peptides in the Regulation of Cardiovascular Physiology and Metabolic Events. 2015 , 4, e002423		80
291	Angiotensin receptor neprilysin inhibitor LCZ696: a novel targeted therapy for arterial hypertension?. 2015 , 1, 260-4		4
290	Vasopeptidase Inhibition Corrects the Structure and Function of the Small Arteries in Experimental Renal Insufficiency. 2015 , 52, 94-102		1
289	The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implications. 2015 , 31, 3-16		77
288	Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. <i>Circulation</i> , 2015 , 131, 54-61	16.7	430
287	Ecallantide for the acute treatment of angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter, randomized, controlled trial. 2015 , 65, 204-13		47
286	Novel RAAS agonists and antagonists: clinical applications and controversies. 2015 , 11, 242-52		94
285	A randomized trial of icatibant in ACE-inhibitor-induced angioedema. 2015 , 372, 418-25		152
284	Prospective Comparison of ARNi with ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF): paragon of a study or further investigation paramount?. <i>Circulation</i> , 2015 , 131, 11-2	16.7	6
283	New approaches in the treatment of hypertension. 2015 , 116, 1074-95		159
282	The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1029-41	15.1	99
281	Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact. 2015 , 21, 741-50		22
280	Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM. 2015 , 49, 1237-51		13
279	Neprilysin, cardiovascular, and Alzheimer's diseases: the therapeutic split?. 2015 , 36, 902-5		48
278	LCZ696 (angiotensin-neprilysin inhibition): the new kid on the heart failure block?. 2015 , 28, 137-45		7
277	Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure. 2015 , 12, 7-14		10
276	LCZ696: the next step in improving RAS inhibition?. 2015 , 17, 37		7

- 275 Neprilysin inhibition in chronic kidney disease. *Nephrology Dialysis Transplantation*, **2015**, 30, 738-43 4.3 63
- 274 Medical Treatment of Heart Failure and Coronary Heart Disease. **2015**, 533-560
- 273 Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. **2015**, 36, 1967-73 58
- 272 Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. **2015**, 17, 242-7 72
- 271 Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. **2015**, 8, 71-8 183
- 270 Drug therapies in older adults (part 2). **2015**, 15, 155-9 5
- 269 Role of the Renin-Angiotensin-Aldosterone System in the Management of Neonatal Heart Failure. **2015**, 16, e575-e585 1
- 268 Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure. **2015**, 37, 2199-205 10
- 267 An update of the blockade of the renin angiotensin aldosterone system in clinical practice. **2015**, 16, 2283-92 19
- 266 The Role of Neprilysin Inhibitors in Cardiovascular Disease. **2015**, 12, 389-94 13
- 265 Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats. **2015**, 88, 109-20 32
- 264 Predictors of Airway Intervention in Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema. **2015**, 153, 544-50 18
- 263 Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. *American Journal of Hypertension*, **2015**, 28, 355-61 2.3 109
- 262 Beneficial Effects of Combined AT1 Receptor/Neprilysin Inhibition (ARNI) Versus AT1 Receptor Blockade Alone in the Diabetic Eye. **2016**, 57, 6722-6730 9
- 261 Should Angiotensin Receptor Neprilysin Inhibitors Replace Angiotensin-converting Enzyme Inhibitors in Heart Failure With a Reduced Ejection Fraction?. **2016**, 2, 47-50 3
- 260 Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease. **2016**, 2016, 8917578 45
- 259 Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date. **2016**, 10, 1627-39 11
- 258 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. **2016**, 22, 659-69 45

257	Calibrating the impact of dual RAAS blockade on the heart and the kidney - balancing risks and benefits. 2016 , 70, 537-53		6
256	Sacubitril/Valsartan: A Novel Cardiovascular Combination Agent. 2016 , 24, 41-7		10
255	Sacubitril/Valsartan (LCZ696) in Heart Failure. 2017 , 243, 133-165		15
254	Pathogenesis of Macrovascular Complications in Diabetes. 2016 , 599-628		1
253	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <i>Circulation</i> , 2016 , 134, e282-92	16.7	253
252	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 176-1408	15.1	452
251	Global cardiovascular protection in chronic kidney disease. 2016 , 13, 603-8		24
250	Love of Angiotensin-Converting Enzyme Inhibitors in the Time of Cholera. 2016 , 4, 403-403		9
249	Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 2043-2051	4.3	22
248	Nepriylisin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck. 2016 , 41, 119-27		10
247	LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure. 2016 , 118, 14-22		22
246	Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm. 2016 , 173, 1911-24		13
245	Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink. 2016 , 82, 1647-1659		23
244	What constitutes optimal neurohumoral antagonism in chronic heart failure?. 2016 , 102, 1922-1932		2
243	Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. 2016 , 18, 1238-1243		44
242	MicroRNA and receptor mediated signaling pathways as potential therapeutic targets in heart failure. 2016 , 20, 1287-1300		9
241	[The new ESC Guidelines for acute and chronic heart failure 2016]. 2016 , 41, 655-663		16
240	Focus on the Novel Cardiovascular Drug LZC696: From Evidence to Clinical Consideration. 2016 , 30, 623-633		6

239	From ARB to ARNI in Cardiovascular Control. 2016 , 18, 86	9
238	Evolving therapies for the management of chronic and acute decompensated heart failure. 2016 , 73, 1745-1754	3
237	Hypertension in Patients with Heart Failure with Reduced Ejection Fraction. 2016 , 18, 127	3
236	Angiotensin-Nepriylsin Inhibition as a Paradigm for All?. 2016 , 18, 115	9
235	Nepriylsin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney. 2016 , 6, 33678	47
234	Sacubitril/valsartan in heart failure: latest evidence and place in therapy. 2016 , 7, 278-290	21
233	Role of Angiotensin Receptor-Nepriylsin Inhibition in Heart Failure. 2016 , 18, 48	9
232	Angioedema Triggered by Medication Blocking the Renin/Angiotensin System: Retrospective Study Using the French National Pharmacovigilance Database. 2016 , 36, 95-102	22
231	WITHDRAWN: The fuster-CNIC-Ferrer cardiovascular polypill: A polypill for secondary cardiovascular prevention. 2016 ,	
230	Nepriylsin Inhibition as a PARADIGM Shift in Heart Failure Therapy. 2016 , 13, 172-80	5
229	Pharmacologic management of angioedema induced by angiotensin-converting enzyme inhibitors. 2016 , 73, 873-9	11
228	Emerging Therapies for Acute and Chronic Heart Failure: Hope or Hype?. 2016 , 29, 46-57	2
227	Combining angiotensin II receptor 1 antagonism and nepriylsin inhibition for the treatment of heart failure. 2016 , 9, 513-523	4
226	A New Mechanism of Action in Heart Failure: Angiotensin-Receptor Nepriylsin Inhibition. 2016 , 32, 116-124	0
225	Combined Angiotensin Receptor Antagonism and Nepriylsin Inhibition. <i>Circulation</i> , 2016 , 133, 1115-24	16.7 115
224	Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook. 2016 , 14, 703-11	4
223	CES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril. 2016 , 72, 681-7	10
222	New medications for heart failure. 2016 , 26, 485-92	13

221	Inhibici3n dual de la neprilisina y del receptor de la angiotensina (ARNI): una alternativa en los pacientes con falla cardiaca. 2016 , 23, 120-127		1
220	Angioedema with renin angiotensin system drugs and neutral endopeptidase inhibitors. 2016 , 10, 387-9		6
219	CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors. 2016 , 16, 220-30		33
218	New Novel Treatment Approaches for Heart Failure With Reduced Ejection Fraction. 2017 , 30, 541-548		
217	Modulation of RAAS-natriuretic peptides in the treatment of HF: Old guys and newcomers. 2017 , 226, 126-131		10
216	Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition. 2017 , 226, 132-135		5
215	Role of Neprilysin Inhibitors in Heart Failure. 2017 , 24, e737-e743		3
214	The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future. 2017 , 93, 29-37		31
213	Heart failure guidelines: What's new?. 2017 , 27, 316-323		4
212	Neprilysin Inhibitors in Cardiovascular Disease. 2017 , 19, 16		2
211	Potential Expanded Indications for Neprilysin Inhibitors. 2017 , 14, 134-145		20
210	Limitations of Sacubitril/Valsartan in the Management of Heart Failure. 2017 , 24, e234-e239		17
209	Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications?. 2017 , 90, 752-759		22
208	Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects. 2017 , 35, e12272		13
207	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. 2017 , 23, 628-651		378
206	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <i>Circulation</i> , 2017 , 135, 127-144	16.7	1503
205	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 776-803	15.1	1064
204	Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. 2017 , 389, 1831-1840		37

203	Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development. 2017 , 13, 103-115	1
202	Angiotensin Receptor-Neprilysin Inhibition. 2017 , 22, 356-364	5
201	Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan. 2017 , 11, 461-468	10
200	Hypertension up to date: SPRINT to SPYRAL. 2017 , 106, 475-484	16
199	Potential beneficial effects of sacubitril-valsartan in renal disease: a new field for a new drug. 2017 , 26, 651-659	9
198	Advances in heart failure: a review of biomarkers, emerging pharmacological therapies, durable mechanical support and telemonitoring. 2017 , 131, 553-566	11
197	A Change of Heart: the New Era of Heart Failure Management. 2017 , 5, 21-27	
196	Long-term neprilysin inhibition - implications for ARNIs. 2017 , 14, 171-186	76
195	Silent disease progression in clinically stable heart failure. 2017 , 19, 469-478	28
194	Neprilysin Inhibition and the Treatment of Heart Failure: Recent Steps in the Right Direction. 2017 , 25, 315-320	1
193	Novel Therapies for Acute Decompensated Heart Failure. 2017 , 177-189	
192	Antihypertensive drug associated angioedema: effect modification by race/ethnicity. 2017 , 26, 1190-1196	7
191	Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs. 2017 , 18, 1143-1153	4
190	Antihypertensive drugs. 2017 , 124, 116-125	104
189	Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema. 2017 , 37, 483-495	26
188	The Clinical Evaluation of Angioedema. 2017 , 37, 449-466	13
187	Neprilysin Inhibitors: Emerging Therapy for Heart Failure. 2017 , 68, 41-49	10
186	The Angiotensin-Converting-Enzyme-Induced Angioedema. 2017 , 37, 183-200	10

185	The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan. 2017 , 13, 1207-1216	18
184	Atrial Natriuretic Peptide - Old But New Therapeutic in Cardiovascular Diseases. 2017 , 81, 913-919	14
183	Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema. 2017 , 2017, 1476402	10
182	Novel approaches for treating hypertension. 2017 , 6, 80	4
181	Cardiac Natriuretic Peptides. 2017 , 3-39	1
180	Neurohormonal Blockade in Heart Failure. 2017 , 3, 19-24	27
179	Treatments for Heart Failure. 2017 , 628-662	1
178	Multiple Avenues of Modulating the Nitric Oxide Pathway in Heart Failure Clinical Trials. 2018 , 15, 44-52	9
177	Angiotensin receptor-neprilysin inhibitor therapy in heart failure: An end that justifies the means. 2018 , 199, 176-177	
176	Sacubitril/Valsartan: From Clinical Trials to Real-world Experience. 2018 , 20, 45	5
175	What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines. 2018 , 20, 39	21
174	B-Natriuretic Peptide Pathway Modulation for the Management of Heart Failure With Reduced Ejection Fraction. 2018 , 32, 1500-1506	1
173	The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond. 2018 , 20, 5	20
172	Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension. 2018 , 20, 351-355	8
171	Evolving Role of Natriuretic Peptides from Diagnostic Tool to Therapeutic Modality. 2018 , 1067, 109-131	8
170	Monitoring Biomarkers in Patients Receiving Neprilysin Inhibitors. 2018 , 6, 8-16	4
169	Utility of natriuretic peptides to assess and manage patients with heart failure receiving angiotensin receptor blocker/neprilysin inhibitor therapy. 2018 , 130, 299-307	13
168	Impact of prolonged utilization of neprilysin inhibition on the cognitive function of heart failure patients. 2018 , 12, 135-139	

167	Perindopril arginine and amlodipine besylate for hypertension: a safety evaluation. 2018 , 17, 207-216		7
166	Heart Failure. 2018 , 298-310		0
165	Enalapril-Induced Angioedema: Two Case Reports in a Rural Health Facility in Kenya. 2018 , 10, e2572		1
164	Sacubitril/Valsartan Averts Adverse Post-Infarction Ventricular Remodeling and Preserves Systolic Function in Rabbits. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 2342-2356	15.1	38
163	Neprilysin Inhibitors and Bradykinin. 2018 , 5, 257		28
162	Molecular Basis for Multiple Omapatrilat Binding Sites within the ACE C-Domain: Implications for Drug Design. <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 10141-10154	8.3	11
161	PARALLEL-HF - A Paradigm Shift for Heart Failure Treatment in Japan?. 2018 , 82, 2479-2480		
160	Sacubitril/valsartan: from a large clinical trial to clinical practice. 2018 , 19, 473-479		5
159	Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study. 2018 , 264, 118-123		19
158	Stable but Progressive Nature of Heart Failure: Considerations for Primary Care Physicians. 2018 , 18, 333-345		11
157	New antihypertensive medications and clinical implications. 2018 , 32, 223-235		5
156	Renin Angiotensin Aldosterone System Blockers. 2018 , 230-241		1
155	National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. 2018 , 27, 1123-1208		141
154	Angioedema Due to Bradykinin Dysregulation. 2018 , 6, 1132-1141		62
153	Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. <i>Circulation</i> , 2018 , 138, 1505-1514	16.7	79
152	Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. 2018 , 12, 2		70
151	ACE Inhibitor-Induced Angioedema: a Review. 2018 , 20, 55		46
150	New Therapeutic Strategies in Heart Failure. 2018 , 565-574		

149	Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction. 2019 , 281, 179-185		5
148	Benefit-risk review of different drug classes used in chronic heart failure. 2019 , 18, 37-49		5
147	Angiotensin receptor neprilysin inhibitors in older patients with heart failure. 2019 , 24, 5-7		1
146	Cardiovascular Pleiotropic Effects of Natriuretic Peptides. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	31
145	Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying Approach. 2019 , 79, 1543-1556		7
144	Heart Failure in Women Due to Hypertensive Heart Disease. 2019 , 15, 497-507		3
143	Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction. 2019 , 49, 469-484		12
142	BNP as a Major Player in the Heart-Kidney Connection. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	22
141	Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. 2019 , 71, 539-570		146
140	The effects of adding angiotensin receptor neprilysin inhibitors to usual care in patients with heart failure: a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. 2019 , 8, 251		3
139	Emerging Drug Classes and Their Potential Use in Hypertension. 2019 , 74, 1075-1083		26
138	New Molecules for Treating Resistant Hypertension: a Clinical Perspective. 2019 , 21, 80		1
137	The renin-angiotensin-aldosterone system and its therapeutic targets. 2019 , 186, 107680		69
136	Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	23
135	Discovery of -glycans on atrial natriuretic peptide (ANP) that affect both its proteolytic degradation and potency at its cognate receptor. 2019 , 294, 12567-12578		28
134	Efficacy and safety of combined neprilysin and RAS inhibition in heart failure: A meta-analysis of randomized controlled trials. 2019 , 293, 159-164		6
133	Neprilysin inhibition: a new therapeutic option for type 2 diabetes?. 2019 , 62, 1113-1122		21
132	Interference With the Renin-Angiotensin System (RAS): Classical Inhibitors and Novel Approaches. 2019 , 523-530		4

131	The historical evolution of knowledge of the involvement of neurohormonal systems in the pathophysiology and treatment of heart failure. 2019 , 38, 883-895		
130	The historical evolution of knowledge of the involvement of neurohormonal systems in the pathophysiology and treatment of heart failure. 2019 , 38, 883-895		2
129	Real-Life Indications to Sacubitril/Valsartan Treatment in Patients With Chronic Systolic Heart Failure. 2019 , 73, 301-306		4
128	Solutions for management of angiotensin-converting enzyme-induced angioedema in a high risk population: a single center retrospective observational study. 2019 , 3, e18-e18		0
127	Neutral Endopeptidase (Nepriylisin) in Therapy and Diagnostics: Yin and Yang. 2019 , 84, 1346-1358		9
126	Telmisartan and thiorphan combination treatment attenuates fibrosis and apoptosis in preventing diabetic cardiomyopathy. 2019 , 115, 373-384		27
125	Practical guidance on the use of sacubitril/valsartan for heart failure. 2019 , 24, 167-176		27
124	Future and Novel Compounds in the Treatment of Diabetic Nephropathy. 2019 , 515-539		2
123	Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation. 2019 , 128, 103-111		6
122	Discovery of TD-0212, an Orally Active Dual Pharmacology AT Antagonist and Nepriylisin Inhibitor (ARNI). 2019 , 10, 86-91		5
121	Chronic kidney disease, heart failure and nepriylisin inhibition. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 558-564	4-3	19
120	Treatment of Heart Failure with Preserved Ejection Fraction. 2020 , 568-585		
119	The rash that presents as a red swollen face. 2020 , 38, 63-78		4
118	Histone deacetylase inhibitor CG200745 ameliorates high-fat diet-induced hypertension via inhibition of angiotensin II production. 2020 , 393, 491-500		6
117	Nepriylisin: A Potential Therapeutic Target of Arterial Hypertension?. 2020 , 16, 25-35		13
116	Effects of Angiotensin-Nepriylisin Inhibition in Canines with Experimentally Induced Cardiorenal Syndrome. 2020 , 26, 987-997		2
115	Sacubitril/Valsartan: Nepriylisin Inhibition 5 Years After PARADIGM-HF. 2020 , 8, 800-810		24
114	Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!. 2021 , 179, 31-71		2

113	Sacubitril/Valsartan in the Management of Heart Failure Patients with Cardiac Implantable Electronic Devices. 2021 , 21, 383-393	3
112	Angioedema, ACE inhibitor and COVID-19. 2020 , 13,	7
111	New and emerging cardiovascular and antihypertensive drugs. 2020 , 19, 1315-1327	3
110	Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data. 2020 , 16, 715-726	5
109	Safety, Pharmacokinetics, and Pharmacodynamics of TD-0714, a Novel Potent Neprilysin Inhibitor in Healthy Adult and Elderly Subjects. 2020 , 13, 1307-1315	
108	Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin-Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 5488-5500	3
107	ARNI in cardiovascular disease: current evidence and future perspectives. 2020 , 16, 505-515	2
106	Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost. 2020 , 178, 114057	22
105	Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor. 2020 , 129, 110410	1
104	An evaluation of the fixed-dose combination sacubitril/valsartan for the treatment of arterial hypertension. 2020 , 21, 1133-1143	6
103	Natriuretic peptides and neprilysin inhibition in hypertension and hypertensive organ damage. 2020 , 132, 170352	4
102	Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment. 2020 , 20, 770-783	9
101	TaleNeprilysin and Neprilysin inhibition in chronic kidney disease. 2021 , 30, 123-130	6
100	Renal protective effect of sacubitril/valsartan in patients with heart failure. 2021 , 11, 4593	2
99	Effectiveness of C1-INH therapy in angiotensin converting enzyme inhibitor induced angioedema. 2021 , 17, 18	3
98	Do neprilysin inhibitors walk the line? Heart ameliorative but brain threatening!. <i>European Journal of Pharmacology</i> , 2021 , 894, 173851	5-3 5
97	Narrative review in the current role of angiotensin receptor-neprilysin inhibitors. 2021 , 9, 518	1
96	A Review on Synthesis, Reactions and Biological Properties of Seven Membered Heterocyclic Compounds: Azepine, Azepane, Azepinone. 2021 , 25, 449-506	8

95	Updates in pharmacotherapy of heart failure with reduced ejection fraction. 2021 , 9, 516		0
94	The Road to Better Management in Resistant Hypertension-Diagnostic and Therapeutic Insights. 2021 , 13,		0
93	Mechanisms and Models in Heart Failure: A Translational Approach. 2021 , 128, 1435-1450		6
92	Efficacy and Safety of LCZ696 for Short-term Management of Essential Hypertension Compared With ARBs: A Meta-analysis of Randomized Controlled Trials. 2021 , 77, 650-659		1
91	Hypertension: Current trends and future perspectives. 2021 , 87, 3721-3736		2
90	Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment. 2021 , 44, 1239-1250		3
89	Cyclic GMP modulating drugs in cardiovascular diseases: Mechanism-based network pharmacology. 2021 ,		1
88	Current concept in the diagnosis, treatment and rehabilitation of patients with congestive heart failure. 2021 , 13, 183-203		1
87	Incidence and risk factors of angiotensin-converting enzyme inhibitor-induced angioedema: A large case-control study. 2021 , 127, 591-592		0
86	Angiotensin Receptor-Nepriylsin Inhibitor (ARNI) and Cardiac Arrhythmias. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5
85	Association of Variants Near the Bradykinin Receptor B Gene With Angioedema in Patients Taking ACE Inhibitors. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 696-709	15.1	2
84	Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats. 2021 , 26,		1
83	Selective Inhibition of the C-Domain of ACE (Angiotensin-Converting Enzyme) Combined With Inhibition of NEP (Nepriylsin): A Potential New Therapy for Hypertension. 2021 , 78, 604-616		0
82	Sacubitril/valsartan in chronic kidney disease: From pharmacological mechanism to clinical application. <i>European Journal of Pharmacology</i> , 2021 , 907, 174288	5.3	0
81	Angiotensin-converting enzyme inhibitor induced angioedema: not always a class effect? A case report and short narrative review. 2021 , 37, 1855-1858		2
80	Critical angioedema induced by a renin angiotensin system blocker in the contemporary era of increasing heart failure: A case report and commentary. 2021 , 23, 692-695		1
79	Myocardial protective effect of sacubitril-valsartan on rats with acute myocardial infarction. 2021 , 267659121990572		
78	Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date. 2021 , 323, 188-191		3

77	Changing Demographics of the Aging Population with Heart Failure and Implications for Therapy. 2014 , 1-14	1
76	Structure-Based Design of Domain-Selective Angiotensin-Converting Enzyme Inhibitors. 2012 , 355-377	1
75	Fixed Low-Dose Antihypertensive Therapy. 2007 , 1061-1073	2
74	Vasoactive Molecules and the Kidney. 2012 , 384-420	2
73	Update on bradykinin-mediated angioedema in 2020. 2020 , 75, 195-205	9
72	Effects of sacubitril/valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction. 2021 , 32, 418-426	4
71	Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy. 2018 , 12, 217-231	12
70	Current Understanding of the Compensatory Actions of Cardiac Natriuretic Peptides in Cardiac Failure: A Clinical Perspective. 2016 , 2, 14-19	9
69	Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696. 2017 , 8, 83323-83333	10
68	LCZ696, a promising novel agent in treating hypertension (a meta-analysis of randomized controlled trials). 2017 , 8, 107991-108005	5
67	Management of heart failure with preserved ejection fraction. 2020 , 43, 12-17	2
66	Management of Patients with Heart Failure: Focus on New Pharmaceutical and Device Options. 2020 , 27, 4522-4535	1
65	Update on the Pharmacotherapy of Heart Failure with Reduced Ejection Fraction. 2020 , 2, 113	5
64	Angiotensin Receptor-Nepriylsin Inhibition (ARNI) in Heart Failure. 2020 , 2, 73	7
63	Diagnosis and management of angioedema with abdominal involvement: a gastroenterology perspective. 2010 , 16, 4913-21	38
62	Angiotensin receptor-nepriylsin inhibitor for the treatment of heart failure: a review of recent evidence. 2020 , 35, 498-513	5
61	Is Entresto good for the brain?. 2017 , 9, 594-599	10
60	Toward a New Paradigm for Targeted Natriuretic Peptide Enhancement in Heart Failure. 2021 , 12, 650124	0

- 59 Vasopeptidase Inhibitors. **2005**, 747-753
- 58 Role of ACE, ACE2 and Neprilysin in the Kidney. **2007**, 1-20
- 57 Physiopathologie des effets secondaires aigus des inhibiteurs de l'enzyme de conversion de l'angiotensine.. **2007**, 191, 1433-1444
- 56 Inhibitors of Angiotensin-Converting Enzyme, Angiotensin II Receptor, Aldosterone, and Renin. **2009**, 112-159
- 55 Chapter 16 Other antihypertensive agents. **2009**,
- 54 Angioedema. **2010**, 117-127
- 53 Approach to and Management of Adverse Drug Reactions. **2010**, 43-48.e2
- 52 Signaling in Hypertension. **2011**, 257-270
- 51 Kapitel E1 Literaturverzeichnis zu Peter, Pichler, Müller-Ladner (Hrsg.): Klinische Immunologie. **2012**, e1-e80
- 50 Antihypertensive Drug Development: A Regulatory Perspective. **2013**, 416-424
- 49 New Drugs for Hypertension. **2013**, 226-229
- 48 Follow-up of Patients with Resistant Hypertension. **2013**, 155-169
- 47 MANAGEMENT OF HYPERTENSION: NEW PERSPECTIVES. *Arterial Hypertension (Russian Federation)*, **2013**, 19, 280-289 0.7
- 46 Management of the Hypertensive Child. **2014**, 1-87
- 45 Aging and Optimal Therapy of Systolic Heart Failure in the Elderly. **2014**, 47-63
- 44 Renin-Angiotensin System. **2015**, 1-51
- 43 Management of the Hypertensive Child. **2016**, 2023-2097
- 42 Novel Therapies for the Prevention and Management of Acute Decompensated Heart Failure. **2016**, 29-71

41	Renin-Angiotensin System. 2016 , 665-707		
40	Novelties in the treatment of heart failure. <i>Vnitřní Lekarství</i> , 2017 , 63, 255-264	0.3	2
39	New dual inhibitor of AT1 receptors and vasopeptidase (LCZ 696) and the PARADIGM HF study. <i>Intervencni A Akutni Kardiologie</i> , 2018 , 17, 36-38	0	1
38	Sacubitril/valsartan (LCZ696) Significantly Reduces Aldosterone and Increases cGMP Circulating Levels in a Canine Model of RAAS Activation.		
37	[A novel agent in the treatment of heart failure with depressed systolic function]. <i>Archivos De Cardiologia De Mexico</i> , 2018 , 88, 287-297	0.2	1
36	Angiotensin-converting enzyme inhibitor-induced angioedema: epidemiology, pathogenesis and management. <i>Vnitřní Lekarství</i> , 2018 , 64, 928-933	0.3	1
35	Key Considerations For Integrating Sacubitril/Valsartan Into Chronic Heart Failure Management. <i>Journal of the Minneapolis Heart Institute Foundation</i> , 2018 , 2, 34-43		
34	Pharmacological Targets of Hypertension. <i>Learning Materials in Biosciences</i> , 2019 , 179-191	0.3	
33	Dual inhibition of at1 receptor for angiotensin ii and neprilysin or sacibtril-valsartan. <i>Interni Medicina Pro Praxi</i> , 2019 , 21, 118-124	0	
32	Pharmacologic Support of the Failing Heart. 2020 , 597-605		
31	Common variants near the bradykinin receptor B2 gene are associated with angioedema induced by angiotensin-converting-enzyme inhibitor treatment - a genome wide association study.		
30	Effect of Angiotensin Receptor-Neprilysin Inhibitor versus Valsartan on Cardiac Status in Patients with Chronic Heart Failure with Reduced Ejection Fraction: A Randomized Clinical Trial in Rangpur Medical College Hospital, Bangladesh. <i>Open Journal of Internal Medicine</i> , 2020 , 10, 21-34	0.2	0
29	The Natriuretic Peptides for Hypertension Treatment. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021 , 1	2.9	3
28	Difficulties in achieving arterial hypertension control. <i>Medica</i> , 2011 , 6, 114-9		
27	Evidence and evidence gaps of medical treatment of non-tumorous diseases of the head and neck. <i>GMS Current Topics in Otorhinolaryngology, Head and Neck Surgery</i> , 2016 , 15, Doc02		
26	Natriuretic peptides: new challenges The solutions. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2021 , 20, 3102	0.9	1
25	Unrecognized recurrent perioperative angioedema requiring intubation in a patient taking long-term angiotensin-converting enzyme inhibitor therapy. <i>Otolaryngology Case Reports</i> , 2022 , 22, 100389	0.3	0
24	Renal events in patients receiving Neprilysin inhibitors: a systematic review and meta-analysis.. <i>Nephrology Dialysis Transplantation</i> , 2022 ,	4.3	0

23	The Design of Multi-target Drugs to Treat Cardiovascular Diseases: Two (or more) Birds on one Stone.. <i>Current Topics in Medicinal Chemistry</i> , 2022 ,	3	0
22	Immunomodulatory Activity of the Most Commonly Used Antihypertensive Drugs-Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	2
21	Probing the Requirements for Dual Angiotensin-Converting Enzyme C-Domain Selective/Nepriylsin Inhibition.. <i>Journal of Medicinal Chemistry</i> , 2022 ,	8.3	0
20	Combining Nepriylsin Inhibitor With ATR Agonist Is Superior to Combination With ATR Blocker in Providing Reno-Protection in Obese Rats.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 778953	5.6	0
19	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <i>Circulation</i> , 2022 , 101161CIR0000000000001063	16.7	35
18	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <i>Journal of the American College of Cardiology</i> , 2022 ,	15.1	49
17	Inhibitors of the renin-angiotensin-aldosterone system. 2013 , 119-168		6
16	Transient Receptor Potential Channels, Natriuretic Peptides, and Angiotensin Receptor-Nepriylsin Inhibitors in Patients With Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9,	5.4	0
15	Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study. <i>European Journal of Pharmacology</i> , 2022 , 928, 175053	5.3	0
14	Emerging trends in sacubitril/valsartan research: A bibliometric analysis of the years 1995-2021. 2022 , 101, e29398		0
13	Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction. 2022 , 155, 113701		0
12	Molecular Mechanism of Blood Pressure Regulation through the Atrial Natriuretic Peptide. 2022 , 11, 1351		1
11	Nepriylsin Inhibitors in Heart Failure. 2022 ,		1
10	Novel antihypertensive agents for resistant hypertension: what does the future hold?.		0
9	Real-World Usage of Sacubitril/Valsartan in Korea: A Multi-Center, Retrospective Study. 2022 , 4, 193		1
8	Efficacy of human C1 esterase inhibitor concentrate for treatment of ACE-inhibitor induced angioedema. 2023 , 64, 121-128		0
7	Angiotensin receptor neprilysin inhibitor use and blood pressure lowering in patients with heart failure with reduced ejection fraction across the spectrum of kidney function: An analysis of the Veterans Administrative Health System.. 2022 ,		0
6	Signaling Pathways and Potential Therapeutic Strategies in Cardiac Fibrosis. 2023 , 24, 1756		0

- 5 Varī de 57 aīs con edema penoescrotal. **2022**, 7, 6-8 ○
- 4 Comparative Risk of Angioedema With Sacubitril-Valsartan vs Renin-Angiotensin-Aldosterone Inhibitors. **2023**, 81, 321-331 ○
- 3 The Real-World Price of Switching to an ARNI. **2023**, 81, 332-335 ○
- 2 Updates for Cardio-Kidney Protective Effects by Angiotensin Receptor-Nepriylsin Inhibitor: Requirement for Additional Evidence of Kidney Protection. ○
- 1 Autoregulation: mediators and renin-angiotensin system in diseases and treatments. **2023**, 9, ○